Navigation Links
n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
Date:9/2/2008

1)

* Difference between groups statistically significant (adjusted analysis; adapted from reference 1)

The GISSI group initiated, designed and conducted the GISSI-HF trial following positive results of a post-hoc analysis of the GISSI-Prevenzione trial (see Notes to Editors) which demonstrated that a subgroup of post-myocardial infarction patients with left ventricular dysfunction had reduced all-cause mortality and hospitalisations with n-3 PUFAs (2).

The primary objectives of the GISSI-HF trial were to demonstrate whether n-3 PUFAs or rosuvastatin improved all-cause mortality or hospitalisations for cardiovascular reasons. Participants were first randomised to receive n-3 PUFAs vs placebo (ORT). A subset of study participants was further randomised to receive rosuvastatin vs placebo.

GISSI-HF-the second large-scale cardiovascular outcome trial of n-3 PUFAs-also confirmed and further supports the safety of n-3 PUFAs, whose cardiovascular benefit in post- myocardial infarction patients had been established by the GISSI-Prevenzione trial (3). Accordingly, current indications of n-3 PUFAs are secondary prevention in post-myocardial infarction patients and treatment of hypertriglyceridaemia. Ongoing studies of n-3 PUFAs in other cardiovascular indications may unveil additional benefits in patients with cardiovascular diseases.

Professor Clemens Von Schacky, Head of Preventive Cardiology, University of Munich, Germany, also reviewed the GISSI-HF trial outcomes and presented the implications of these results for clinical practice during a Solvay-sponsored symposium at ESC 2008. He commented. "Very recently, we have seen a number of large outcome trials in congestive heart failure using a variety of approaches. Unfortunately, these were either neutral or negative. In sharp contrast, GISSI-HF, a meticulously conducted trial, reported the safety and efficacy of n-3 PUFAs in this patient population. Thus, evidence has been provided for guid
'/>"/>

SOURCE Solvay Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. New Study: Pine Bark Significantly Reduces Menstrual Pain
6. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
10. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
11. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)...  Denovo Biopharma, LLC, today announced that it ... Eli Lilly and Company (NYSE:  LLY). Denovo gains ... globally, including transfer of all intellectual property and ... Lilly developed enzastaurin in a variety of indications, ... trials for diffuse large B-cell lymphoma (DLBCL). In ...
(Date:9/16/2014)... -- EHE International, the recognized leader in preventive medicine and ... that David Abrams M.D . in Tarzana, ... center. Through David Abrams M.D ., EHE members in ... access to EHE,s preventive care programs to help proactively maintain ... Dr. Abrams M.D. to its growing private provider network. With ...
(Date:9/16/2014)... , Sept. 16, 2014  Advanced Medical ... stage development company engaged primarily in the ... for diagnostic and therapeutic applications, today announced ... related to its brachytherapy products.  AMIC,s rights ... its license from Battelle, under which AMIC ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2EHE International Certifies David Abrams M.D. as Its Newest Partner 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... guide low-income,and minority cancer patients through cancer treatment, ... major obstacles that prevent them,from receiving quality care ... October 28, 2007, at the American Society for ... Angeles. Minority and low-income cancer patients continue ...
... FLUSHING, N.Y., Oct. 30 The following is,being issued by New York Hospital Queens:, ... aureus(MRSA) is scheduled for ... James Rahal, M.D., and a team of infectious disease ... will address the ...
Cached Medicine Technology:Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments 2Hospital to Hold MRSA Briefing for Media and Community Leaders 2
(Date:9/16/2014)... CALIF. (PRWEB) September 16, 2014 ... and customer service solutions, announced today that the ... in Learning Award for the creation of a ... contractor agents. Brandon Hall Group honors companies that ... processes, systems and tools that have helped companies ...
(Date:9/16/2014)... 2014 As part of Child Passenger ... Saturday, Sept. 20, Amica Insurance is reminding ... and secure while in the car. , According to ... Safety Administration (NHTSA), 20 percent of drivers of ... manual when installing child restraints. However, 90 percent of ...
(Date:9/16/2014)... 2014 RxAnte, the leading platform ... targeted clinical programs, today announced key changes to ... Company’s drive to improve medication effectiveness through the ... On September 2, 2014, Brock Hardaway, chief executive ... that RxAnte founder and President Josh Benner has ...
(Date:9/16/2014)... Hudson County, NJ (PRWEB) September 16, 2014 ... that a leading Bariatric Surgeon, Leigh Montes, MD, ... of Bariatric Surgery at Christ Hospital. Our system ... Bariatric Center, a medical and surgical weight loss ... through the most advanced bariatric surgery procedures, including ...
(Date:9/16/2014)... 2014 Regulatory intelligence (RI), the ... has become a crucial skill for regulatory professionals ... sectors. Regulatory Intelligence 101 , new from ... serves as an essential guide to the basics ... examines available regulatory intelligence tools, both free and ...
Breaking Medicine News(10 mins):Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:RAPS Publishes Regulatory Intelligence 101 Book 2
... who showed that a single prostate specific antigen (PSA) test ... prostate cancer up to 25 years later, (regardless of clinical ... used to predict advanced prostate cancer. , The findings, ... help physicians identify which men would benefit from intensive screening. ...
... for,International Development (USAID) announced a $70 million, five-year,program ... countries.,Fistula Care aims to increase access to emergency ... their capacity to provide surgical,fistula repair. The program ... increase understanding about obstetric fistula and steps to,prevent ...
... His Royal Highness, The Duke of York,was the ... to mark the United States,launch of UK-based specialty ... US product, Sancuso, is currently under,consideration for licensing ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 ), Prince Andrew ...
... the human cell, certain proteins are the production managers, ... the National Institute of General Medical Sciences (NIGMS), part ... clearer understanding of how a key protein controls gene ... disease. The work could provide new avenues to design ...
... MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the first quarter, ended,December 31, ... Highlights: - EP Revenue for Q1 2008 ... over Q1 2007. All regions around ...
... SANTA MONICA, Calif., Feb. 14 /PRNewswire-USNewswire/ - The ... letter to the state,s HMO,regulator calling for swift ... as "double agents," combing medical records for any,excuse ... Governor Arnold Schwarzenegger told the Los Angeles Times ...
Cached Medicine News:Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:USAID Awards $70 Million for the Prevention and Treatment of Obstetric Fistula 2Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 2Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 3Health News:Enzyme structure reveals new drug targets for cancer and other diseases 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 3Health News:CryoCath Announces Fiscal 2008 First Quarter Results 4Health News:CryoCath Announces Fiscal 2008 First Quarter Results 5Health News:CryoCath Announces Fiscal 2008 First Quarter Results 6Health News:CryoCath Announces Fiscal 2008 First Quarter Results 7Health News:CryoCath Announces Fiscal 2008 First Quarter Results 8Health News:CryoCath Announces Fiscal 2008 First Quarter Results 9Health News:CryoCath Announces Fiscal 2008 First Quarter Results 10Health News:CryoCath Announces Fiscal 2008 First Quarter Results 11Health News:FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: